Dennis Bourdette

Dennis Bourdette

Auto-generated profile, based on publicly available information

Dennis Bourdette

Neurology, Oregon Health & Science University, Portland, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MFMichael Forte
Michael Forte
BGBruce G. Gold
Bruce G. Gold
GMGail Marracci
Gail Marracci
PCPriya Chaudhary
Priya Chaudhary
EBEmy Basso
Emy Basso
DBDennis Bourdette
Dennis Bourdette
Multiple sclerosis (MS) is the leading cause of neurological disability in young adults, affecting some two million people worldwide. Traditionally, MS has been considered a chronic, inflammatory disorder of the central white matter in which ensuing demyelination results in physical disability [Frohman EM, Racke MK, Raine CS (2006) N Engl J Med 354:942–955]. More recently, MS has become increasingly viewed as a neurodegenerative disorder in which neuronal loss, axonal injury, and atrophy of the CNS lead to permanent neurological and clinical disability. Although axonal pathology and loss in MS has been recognized for >100 years, very little is known about the underlying molecular mechanisms. Progressive axonal loss in MS may stem from a cascade of ionic imbalances initiated by inflammation, leading to mitochondrial dysfunction and energetic deficits that result in mitochondrial and cellular Ca 2+ overload. In a murine disease model, experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (CyPD), a key regulator of the mitochondrial permeability transition pore (PTP), developed EAE, but unlike WT mice, they partially recovered. Examination of the spinal cords of CyPD-knockout mice revealed a striking preservation of axons, despite a similar extent of inflammation. Furthermore, neurons prepared from CyPD-knockout animals were resistant to reactive oxygen and nitrogen species thought to mediate axonal damage in EAE and MS, and brain mitochondria lacking CyPD sequestered substantially higher levels of Ca 2+ . Our results directly implicate pathological activation of the mitochondrial PTP in the axonal damage occurring during MS and identify CyPD, as well as the PTP, as a potential target for MS neuroprotective therapies.

18 June 2012 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
CFCheng Fang
Cheng Fang
DBDennis Bourdette
Dennis Bourdette
GBGary Banker
Gary Banker
Background: Reactive oxygen species (ROS) released by microglia and other inflammatory cells can cause axonal degeneration. A reduction in axonal transport has also been implicated as a cause of axonal dystrophies and neurodegeneration, but there is a paucity of experimental data concerning the effects of ROS on axonal transport. We used live cell imaging to examine the effects of hydrogen peroxide on the axonal transport of mitochondria and Golgi-derived vesicles in cultured rat hippocampal neurons. Results: Hydrogen peroxide rapidly inhibited axonal transport, hours before any detectable changes in mitochondrial morphology or signs of axonal degeneration. Mitochondrial transport was affected earlier and was more severely inhibited than the transport of Golgi-derived vesicles. Anterograde vesicle transport was more susceptible to peroxide inhibition than retrograde transport. Axonal transport partially recovered following removal of hydrogen peroxide and local application of hydrogen peroxide inhibited transport, suggesting that the effects were not simply a result of nerve cell death. Sodium azide, an ATP synthesis blocker, had similar effects on axonal transport, suggesting that ATP depletion may contribute to the transport inhibition due to hydrogen peroxide. Conclusions: These results indicate that inhibition of axonal transport is an early consequence of exposure to ROS and may contribute to subsequent axonal degeneration.

1 August 2009 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
KSKimmy G. Su
Kimmy G. Su
GBGary Banker
Gary Banker
DBDennis Bourdette
Dennis Bourdette
MFMichael Forte
Michael Forte

18 April 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
MHMeredith D. Hartley
Meredith D. Hartley
TBTania Banerji
Tania Banerji
ITIan J. Tagge
Ian J. Tagge
LKLisa L. Kirkemo
Lisa L. Kirkemo
PCPriya Chaudhary
Priya Chaudhary
TSThomas S. Scanlan
Thomas S. Scanlan
Oligodendrocyte processes wrap axons to form neuroprotective myelin sheaths, and damage to myelin in disorders, such as multiple sclerosis (MS), leads to neurodegeneration and disability. There are currently no approved treatments for MS that stimulate myelin repair. During development, thyroid hormone (TH) promotes myelination through enhancing oligodendrocyte differentiation; however, TH itself is unsuitable as a remyelination therapy due to adverse systemic effects. This problem is overcome with selective TH agonists, sobetirome and a CNS-selective prodrug of sobetirome called Sob-AM2. We show here that TH and sobetirome stimulated remyelination in standard gliotoxin models of demyelination. We then utilized a genetic mouse model of demyelination and remyelination, in which we employed motor function tests, histology, and MRI to demonstrate that chronic treatment with sobetirome or Sob-AM2 leads to significant improvement in both clinical signs and remyelination. In contrast, chronic treatment with TH in this model inhibited the endogenous myelin repair and exacerbated disease. These results support the clinical investigation of selective CNS-penetrating TH agonists, but not TH, for myelin repair.

24 January 2011 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
ABAnna Barsukova
Anna Barsukova
AKAlexander Komarov
Alexander Komarov
GHGyörgy Hajnóczky
György Hajnóczky
Paolo BernardiPaolo Bernardi
Paolo Bernardi
DBDennis Bourdette
Dennis Bourdette
MFMichael Forte
Michael Forte

1 January 2013 in Frontiers in Physiology
Verified
Journal Article
Open access
KSKimmy Su
Kimmy Su
DBDennis Bourdette
Dennis Bourdette
MFMichael Forte
Michael Forte
Multiple sclerosis (MS) has traditionally been considered an autoimmune inflammatory disorder leading to demyelination and clinical debilitation as evidenced by our current standard anti-inflammatory and immunosuppressive treatment regimens. While these approaches do control the frequency of clinical relapses, they do not prevent the progressive functional decline that plagues many people with MS. Many avenues of research indicate that a neurodegenerative process may also play a significant role in MS from the early stages of disease, and one of the current hypotheses identifies mitochondrial dysfunction as a key contributing mechanism. We have hypothesized that pathological permeability transition pore (PTP) opening mediated by reactive oxygen species (ROS) and calcium dysregulation is central to mitochondrial dysfunction and neurodegeneration in MS. This focused review highlights recent evidence supporting this hypothesis, with particular emphasis on our in vitro and in vivo work with the mitochondria-targeted redox enzyme p66ShcA.